- socially bharat
- December 10, 2024
BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline Assets
San Mateo, Calif., United States: 5-year follow-up from SEQUOIA study demonstrated treatment with BRUKINSA reduced the risk of progression
